Ankylosing spondylitis and bowel disease

Best Practice and Research: Clinical Rheumatology

Volumn 20, Issue 3, 2006, Pages 451-471

  Rudwaleit, Martin ^a   Baeten, Dominique ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

ankylosing spondylitis; CARD15; Crohn's disease; HLA B27; inflammatory bowel disease; spondyloarthritis; tumour necrosis factor

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CORTICOSTEROID; ETANERCEPT; HLA B27 ANTIGEN; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ANTIBODY;

ANKYLOSING SPONDYLITIS; CLINICAL TRIAL; COLITIS; COLONOSCOPY; COMORBIDITY; CROHN DISEASE; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG EFFICACY; DRUG INDUCED DISEASE; ENTERITIS; EVIDENCE BASED MEDICINE; GENE MUTATION; HEALING; HISTOPATHOLOGY; HUMAN; IDIOPATHIC DISEASE; IMMUNOPATHOLOGY; INNATE IMMUNITY; INTESTINE ENDOSCOPY; INTESTINE MUCOSA; MEDICAL DECISION MAKING; PATHOPHYSIOLOGY; PHYSIOTHERAPY; PRIORITY JOURNAL; REMISSION; REVIEW; RISK ASSESSMENT; SCREENING TEST; SPONDYLOARTHROPATHY; SYMPTOMATOLOGY; SYNOVIUM; TREATMENT PLANNING; ULCERATIVE COLITIS;

COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; SPONDYLITIS, ANKYLOSING;

EID: 33744931901     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2006.03.010     Document Type: Review

References (124)

1. Wright V. Seronegative polyarthritis: a unified concept. Arthritis and Rheumatism 21 (1978) 619-633
2. Dougados M., van der Linden S., Juhlin R., et al. The European spondylarthropathy study group preliminary criteria for the classification of spondylarthropathy. Arthritis and Rheumatism 34 (1991) 1218-1227
3. Amor B., Dougados M., and Mijiyawa M. Criteria of the classification of spondylarthropathies. Revue du Rhumatisme et des Maladies Osteo-Articulaires 57 (1990) 85-89
4. Sieper J., Braun J., Rudwaleit M., et al. Ankylosing spondylitis: an overview. Annals of the Rheumatic Diseases 61 supplement 3 (2002) iii1-iii8
5. De Keyser F., Elewaut D., De Vos M., et al. Bowel inflammation and the spondyloarthropathies. Rheumatic Diseases Clinics of North America 24 (1998) 785-813
6. Leirisalo-Repo M. Prognosis, course of disease, and treatment of the spondyloarthropathies. Rheumatic Diseases Clinics of North America 24 (1998) 737-751
7. Moller P., Vinje O., Kass E., and Berg K. The distribution of clinical findings in Bechterew's syndrome (ankylosing spondylitis) suggests distinct genetic subgroups. Clinical Genetics 22 (1982) 151-159
8. Purrmann J., Zeidler H., Bertrams J., et al. HLA antigens in ankylosing spondylitis associated with Crohn's disease. Increased frequency of the HLA phenotype B27, B44. The Journal of Rheumatology 15 (1988) 1658-1661
9. de Vlam K., Mielants H., Cuvelier C., et al. Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. The Journal of Rheumatology 27 (2000) 2860-2865
10. Brophy S., Pavy S., Lewis P., et al. Inflammatory eye, skin, and bowel disease in spondyloarthritis: genetic, phenotypic, and environmental factors. The Journal of Rheumatology 28 (2001) 2667-2673
11. Leirisalo-Repo M., Turunen U., Stenman S., et al. High frequency of silent inflammatory bowel disease in spondylarthropathy. Arthritis and Rheumatism 37 (1994) 23-31
12. Mielants H., Veys E.M., Cuvelier C., and De Vos M. Ileocolonoscopic findings in seronegative spondylarthropathies. British Journal of Rheumatology 27 (1988) S95-S105
13. Mielants H., Veys E.M., De Vos M., et al. The evolution of spondyloarthropathies in relation to gut histology. I. Clinical aspects. The Journal of Rheumatology 22 (1995) 2266-2272
14. Mielants H., Veys E.M., Cuvelier C., et al. The evolution of spondyloarthropathies in relation to gut histology. II. Histological aspects. The Journal of Rheumatology 22 (1995) 2273-2278
15. Mielants H., Veys E.M., Cuvelier C., et al. The evolution of spondyloarthropathies in relation to gut histology. III. Relation between gut and joint. The Journal of Rheumatology 22 (1995) 2279-2284
16. Smale S., Natt R.S., Orchard T.R., et al. Inflammatory bowel disease and spondylarthropathy. Arthritis and Rheumatism 44 (2001) 2728-2736
17. Martinez-Gonzalez O., Cantero-Hinojosa J., Paule-Sastre P., et al. Intestinal permeability in patients with ankylosing spondylitis and their healthy relatives. British Journal of Rheumatology 33 (1994) 644-647
18. Vaile J.H., Meddings J.B., Yacyshyn B.R., et al. Bowel permeability and CD45RO expression on circulating CD20+B cells in patients with ankylosing spondylitis and their relatives. The Journal of Rheumatology 26 (1999) 128-135
19. Orchard T.R., Wordsworth B.P., and Jewell D.P. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut 42 (1998) 387-391
20. van der Linden S., Valkenburg H.A., and Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis and Rheumatism 27 (1984) 361-368
21. Palm O., Moum B., Ongre A., and Gran J.T. Prevalence of ankylosing spondylitis and other spondyloarthropathies among patients with inflammatory bowel disease: a population study (the IBSEN study). The Journal of Rheumatology 29 (2002) 511-515
22. Peeters H., Van der Cruyssen B., Laukens D., et al. Radiological sacroiliitis, a hallmark of spondylitis, is linked with CARD15 gene polymorphisms in patients with Crohn's disease. Annals of the Rheumatic Diseases 63 (2004) 1131-1134
23. Podswiadek M., Punzi L., Stramare R., et al. The prevalence of radiographic sacroiliitis in patients affected by inflammatory bowel disease with inflammatory low back pain. Reumatismo 56 (2004) 110-113
24. Steer S., Jones H., Hibbert J., et al. Low back pain, sacroiliitis, and the relationship with HLA-B27 in Crohn's disease. The Journal of Rheumatology 30 (2003) 518-522
25. Queiro R., Maiz O., Intxausti J., et al. Subclinical sacroiliitis in inflammatory bowel disease: a clinical and follow-up study. Clinical Rheumatology 19 (2000) 445-449
26. Colbert R.A. The immunobiology of HLA-B27: variations on a theme. Current Molecular Medicine 4 (2004) 21-30
27. Brown M.A., Kennedy L.G., MacGregor A.J., et al. Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and the environment. Arthritis and Rheumatism 40 (1997) 1823-1828
28. Sims A.M., Wordsworth B.P., and Brown M.A. Genetic susceptibility to ankylosing spondylitis. Current Molecular Medicine 4 (2004) 13-20
29. Enlow R.W., Bias W.B., and Arnett F.C. The spondylitis of inflammatory bowel disease. Evidence for a non-HLA linked axial arthropathy. Arthritis and Rheumatism 23 (1980) 1359-1365
30. Hugot J.P., Chamaillard M., Zouali H., et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411 (2001) 599-603
31. Crane A.M., Bradbury L., van Heel D.A., et al. Role of NOD2 variants in spondylarthritis. Arthritis and Rheumatism 46 (2002) 1629-1633
32. Miceli-Richard C., Zouali H., Lesage S., et al. CARD15/NOD2 analyses in spondylarthropathy. Arthritis and Rheumatism 46 (2002) 1405-1406
33. D'Amato M. The Crohn's associated NOD2 3020InsC frameshift mutation does not confer susceptibility to ankylosing spondylitis. The Journal of Rheumatology 29 (2002) 2470-2471
34. van der Paardt M., Crusius J.B., de Koning M.H., et al. CARD15 gene mutations are not associated with ankylosing spondylitis. Genes and Immunity 4 (2003) 77-78
35. Ferreiros-Vidal I., Amarelo J., Barros F., et al. Lack of association of ankylosing spondylitis with the most common NOD2 susceptibility alleles to Crohn's disease. The Journal of Rheumatology 30 (2003) 102-104
36. Laukens D., Peeters H., Marichal D., et al. CARD15 gene polymorphisms in patients with spondyloarthropathies identify a specific phenotype previously related to Crohn's disease. Annals of the Rheumatic Diseases 64 (2005) 930-935
37. Bjarnason I., Helgason K.O., Geirsson A.J., et al. Subclinical intestinal inflammation and sacroiliac changes in relatives of patients with ankylosing spondylitis. Gastroenterology 125 (2003) 1598-1605
38. Mielants H., Veys E.M., Cuvelier C., et al. Gut inflammation in children with late onset pauci-articular juvenile chronic arthritis and evolution to adult spondyloarthropathy: a prospective study. The Journal of Rheumatology 20 (1993) 1567-1572
39. Schatteman L., Mielants H., Veys E.M., et al. Gut inflammation in psoriatic arthritis: a prospective ileocolonoscopic study. The Journal of Rheumatology 22 (1995) 680-683
40. Cuvelier C., Barbatis C., Mielants H., et al. Histopathology of intestinal inflammation related to reactive arthritis. Gut 28 (1987) 394-401
41. Demetter P., Van Huysse J.A., De Keyser F., et al. Increase in lymphoid follicles and leukocyte adhesion molecules emphasizes a role for the gut in spondyloarthropathy pathogenesis. The Journal of Pathology 198 (2002) 517-522
42. De Vos M., Mielants H., Cuvelier C., et al. Long-term evolution of gut inflammation in patients with spondyloarthropathy. Gastroenterology 110 (1996) 1696-1703
43. Demetter P., De Vos M., Van Damme N., et al. Focal upregulation of E-cadherin-catenin complex in inflamed bowel mucosa but reduced expression in ulcer-associated lineage. American Journal of Clinical Pathology 114 (2000) 364-370
44. Demetter P., Baeten D., De Keyser F., et al. Subclinical gut inflammation in spondyloarthropathy patients is associated with upregulation of the E-cadherin/catenin complex. Annals of the Rheumatic Diseases 59 (2000) 211-216
45. Elewaut D., De Keyser F., Cuvelier C., et al. Distinctive activated cellular subsets in colon from patients with Crohn's disease and ulcerative colitis. Scandinavian Journal of Gastroenterology 33 (1998) 743-748
46. Elewaut D., De Keyser F., Van den Bosch F., et al. Enrichment of T cells carrying beta7 integrins in inflamed synovial tissue from patients with early spondyloarthropathy, compared to rheumatoid arthritis. The Journal of Rheumatology 25 (1998) 1932-1937
47. Van Damme N., Elewaut D., Baeten D., et al. Gut mucosal T cell lines from ankylosing spondylitis patients are enriched with alphaEbeta7 integrin. Clinical and Experimental Rheumatology 19 (2001) 681-687
48. Van Damme N., De Keyser F., Demetter P., et al. The proportion of Th1 cells, which prevail in gut mucosa, is decreased in inflammatory bowel syndrome. Clinical and Experimental Immunology 125 (2001) 383-390
49. Van Damme N., De Vos M., Baeten D., et al. Flow cytometric analysis of gut mucosal lymphocytes supports an impaired Th1 cytokine profile in spondyloarthropathy. Annals of the Rheumatic Diseases 60 (2001) 495-499
50. Demetter P., De Vos M., Van Huysse J.A., et al. Colon mucosa of both spondyloarthritis and Crohn's disease patients is enriched with macrophages expressing the scavenger receptor CD163. Annals of the Rheumatic Diseases 64 (2005) 321-324
51. Ogura Y., Bonen D.K., Inohara N.R., et al. frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411 (2001) 603-606
52. Hoffman I.E., Demetter P., Peeters M., et al. Anti-Saccharomyces cerevisiae IgA antibodies are raised in ankylosing spondylitis and undifferentiated spondyloarthropathy. Annals of the Rheumatic Diseases 62 (2003) 455-459
53. Torok H.P., Glas J., Gruber R., et al. Inflammatory bowel disease-specific autoantibodies in HLA-associated spondyloarthropathies: increased prevalence of AS pANCA. Digestion 70 (2004) 49-54
54. Vander Cruyssen B.V., Peeters H., Hoffman I.E., et al. CARD15 polymorphisms are associated with anti-Saccharomyces cerevisiae antibodies in caucasian Crohn's disease patients. Clinical and Experimental Immunology 140 (2005) 354-359
55. Severijnen A.J., Hazenberg M.P., and Van De Merwe J.P. Induction of chronic arthritis in rats by cell wall fragments of anaerobic coccoid rods isolated from the faecal flora of patients with Crohn's disease. Digestion 39 (1988) 118-125
56. Severijnen A.J., Van Kleef R., Hazenberg P., and Van de Merwe J.P. Cell wall fragments from major residents of the human intestinal flora induce chronic arthritis in rats. The Journal of Rheumatology 16 (1989) 1061-1068
57. Mansson I., Norberg R., Olhagen B., and Bjorklund N.E. Arthritis in pigs induced by dietary factor: microbiological, clinical and histological studies. Clinical and Experimental Immunology 9 (1971) 677-693
58. Hammer R.E., Maika S.D., Richardson J.A., et al. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human b2m: an animal model of HLA-B27-associated human disorders. Cell 63 (1990) 109-112
59. Taurog J.D., Richardson J.A., Croft J.T., et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. The Journal of Experimental Medicine 180 (1994) 2359-2364
60. Breban M., Fernandez-Sueiro J.L., Richardson J.A., et al. T cells, but not thymic exposure to HLA-B27, are required for the inflammatory disease of HLA-B27 transgenic rats. Journal of Immunology 156 (1996) 794-803
61. May E., Dorris M.L., Satumtira N., et al. CD8 alpha beta T cells are not essential to the pathogenesis of arthritis and colitis in HLA-B27 transgenic rats. Journal of Immunology 170 (2003) 1099-1105
62. Tran T.M., Satumtira N., Dorris M.L., et al. HLA-B27 in transgenic rats form disulfide-linked heavy chain oligomers and multimers that bind to the chaperone BiP. Journal of Immunology 172 (2004) 5110-5119
63. Cuvelier C.A., De Wever N., Mielants H., et al. Expression of T cell receptors alpha beta and gamma delta in the ileal mucosa of patients with Crohn's disease and with spondyloarthropathy. Clinical and Experimental Immunology 90 (1992) 275-279
64. Baeten D., Demetter P., Cuvelier C., et al. Comparative study of the synovial histology in rheumatoid arthritis, spondyloarthropathy, and osteoarthritis: influence of disease duration and activity. Annals of the Rheumatic Diseases 59 (2000) 945-953
65. Laloux L., Voisin M.C., Allain J., et al. Immunohistological study of the entheses in spondyloarthropathies: comparison in rheumatoid arthritis and osteoarthritis. Annals of the Rheumatic Diseases 60 (2001) 316-321
66. Mertz A.K., Wu P., Sturniolo T., et al. Multispecific CD4+T cell response to a single 12-mer epitope of the immunodominant heat-shock protein 60 of Yersinia enterocolitica in yersinia-triggered reactive arthritis: overlap with the B27-restricted CD8 epitope, functional properties, and epitope presentation by multiple DR alleles. Journal of Immunology 164 (2000) 1529-1537
67. Kuon W., Holzhutter H.G., Appel H., et al. Identification of HLA-B27-restricted peptides from the Chlamydia trachomatis proteome with possible relevance to HLA-B27-associated disease. Journal of Immunology 167 (2001) 4738-4746
68. Thiel A., Wu P., Lauster R., et al. Analysis of the antigen-specific T cell response in reactive arthritis by flow cytometry. Arthritis and Rheumatism 43 (2000) 2834-2842
69. Goodall J.C., Beacock-Sharp H., Deane K.H., and Gaston J.S. Recognition of the 60 kilodalton cysteine-rich outer membrane protein OMP2 by CD4+T cells from humans infected with Chlamydia trachomatis. Clinical and Experimental Immunology 126 (2001) 488-493
70. Duchmann R., Lambert C., May E., et al. CD4+ and CD8+ clonal T cell expansions indicate a role of antigens in ankylosing spondylitis; a study in HLA-B27+ monozygotic twins. Clinical and Experimental Immunology 123 (2001) 315-322
71. Salmi M., and Jalkanen S. Human leucocyte subpopulations from inflamed gut bind to joint vasculature using distinct sets of adhesion molecules. Journal of Immunology 166 (2001) 4650-4657
72. Baeten D., Kruithof E., Van den Bosch E., et al. Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondyloarthropathy: histologic findings in eight patients from an open-label pilot study. Arthritis and Rheumatism 44 (2001) 186-195
73. Yin Z., Braun J., Neure L., et al. Crucial role of interleukin-10/interleukin-12 balance in the regulation of the type 2 T helper cytokine response in reactive arthritis. Arthritis and Rheumatism 40 (1997) 1788-1797
74. Rudwaleit M., Siegert S., Yin Z., et al. Low T cell production of TNFalpha and IFNgamma in ankylosing spondylitis: its relation to HLA-B27 and influence of the TNF-308 gene polymorphism. Annals of the Rheumatic Diseases 60 (2001) 36-42
75. Baeten D., Van Damme N., Van den Bosch F., et al. Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNFalpha. Annals of the Rheumatic Diseases 60 (2001) 750-755
76. Yin Z., Siegert S., Neure L., et al. The elevated ratio of interferon gamma-/interleukin-4-positive T cells found in synovial fluid and synovial membrane of rheumatoid arthritis patients can be changed by interleukin-4 but not by interleukin-10 or transforming growth factor beta. Rheumatology 38 (1999) 1058-1067
77. Canete J.D., Martinez S.E., Farres J., et al. Differential Th1/Th2 cytokine patterns in chronic arthritis: interferon gamma is highly expressed in synovium of rheumatoid arthritis compared with seronegative spondyloarthropathies. Annals of the Rheumatic Diseases 59 (2000) 263-268
78. Braun J., Yin Z., Spiller I., et al. Low secretion of tumor necrosis factor alpha, but no other Th1 or Th2 cytokines, by peripheral blood mononuclear cells correlates with chronicity in reactive arthritis. Arthritis and Rheumatism 42 (1999) 2039-2044
79. Baeten D., Demetter P., Cuvelier C.A., et al. Macrophages expressing the scavenger receptor CD163: a link between immune alterations of the gut and synovial inflammation in spondyloarthropathy. The Journal of Pathology 196 (2002) 343-350
80. Baeten D., Kruithof E., De Rycke L., et al. Infiltration of the synovial membrane with macrophage subsets and polymorphonuclear cells reflects global disease activity in spondyloarthropathy. Arthritis Research & Therapy 7 (2005) R359-R369
81. Baeten D., Moller H.J., Delanghe J., et al. Association of CD163 positive macrophages and local production of CD163 with decreased lymphocyte activation in spondyloarthropathy synovitis. Arthritis and Rheumatism 50 (2004) 1611-1623
82. Cario E., and Podolsky D.K. Differential alteration in intestinal epithelial cell expression of Toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infection and Immunity 68 (2000) 7010-7017
83. De Rycke L., Vandooren B., Kruithof E., et al. Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of Toll-like receptor 2 and Toll-like receptor 4 in spondylarthropathy. Arthritis and Rheumatism 52 (2005) 2146-2158
84. Braun J., Bollow M., Neure L., et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis and Rheumatism 38 (1995) 499-505
85. Danning C.L., Illei G.G., Hitchon C., et al. Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis and Rheumatism 43 (2000) 1244-1256
86. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 115 (1998) 182-205
87. Zochling J., van der Heijde D., Burgos-Vargas R., et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Annals of the Rheumatic Diseases 65 4 (2006) 442-452
88. Rampton D.S., and Sladen G.E. Relapse of ulcerative proctocolitis during treatment with non-steroidal anti-inflammatory drugs. Postgraduate Medical Journal 57 (1981) 297-299
89. Felder J.B., Korelitz B.I., Rajapakse R., et al. Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study. The American Journal of Gastroenterology 95 (2000) 1949-1954
90. Kaufmann H.J., and Taubin H.L. Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease. Annals of Internal Medicine 107 (1987) 513-516
91. Cipolla G., Crema F., Sacco S., et al. Nonsteroidal anti-inflammatory drugs and inflammatory bowel disease: current perspectives. Pharmacological Research 46 (2002) 1-6
92. Evans J.M., McMahon A.D., Murray F.E., et al. Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease. Gut 40 (1997) 619-622
93. Bonner G.F., Walczak M., Kitchen L., and Bayona M. Tolerance of nonsteroidal antiinflammatory drugs in patients with inflammatory bowel disease. The American Journal of Gastroenterology 95 (2000) 1946-1948
94. Bonner G.F., Fakhri A., and Vennamaneni S.R. A long-term cohort study of nonsteroidal anti-inflammatory drug use and disease activity in outpatients with inflammatory bowel disease. Inflammatory Bowel Diseases 10 (2004) 751-757
95. Dougados M., Dijkmans B., Khan M., et al. Conventional treatments for ankylosing spondylitis. Annals of the Rheumatic Diseases 61 supplement 3 (2002) iii40-iii50
96. Haibel H., Rudwaleit M., Braun J., and Sieper J. Six months open label trial of leflunomide in active ankylosing spondylitis. Annals of the Rheumatic Diseases 64 (2005) 124-126
97. Haibel H., Rudwaleit M., Listing J., and Sieper J. Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Annals of the Rheumatic Diseases 64 (2005) 296-298
98. Van Den Bosch F., Kruithof E., Baeten D., et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis and Rheumatism 46 (2002) 755-765
99. Braun J., Brandt J., Listing J., et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359 (2002) 1187-1193
100. Gorman J.D., Sack K.E., and Davis Jr. J.C. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. The New England Journal of Medicine 346 (2002) 1349-1356
101. Brandt J., Listing J., Haibel H., et al. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. Rheumatology (Oxford, England) 44 (2005) 342-348
102. Braun J., and Sieper J. Biological therapies in the spondyloarthritides-the current state. Rheumatology (Oxford, England) 43 (2004) 1072-1084
103. van der Heijde D., Dijkmans B., Geusens P., et al. Ankylosing spondylitis study for the evaluation of recombinant infliximab therapy study group. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis and Rheumatism 52 (2005) 582-591
104. Rudwaleit M., and Sieper J. Infliximab for the treatment of ankylosing spondylitis. Expert Opinion on Biological Therapy 5 (2005) 1095-1109
105. Haibel H, Rudwaleit M, Brandt HC, et al. Adalimumab reduces spinal symptoms in active ankylosing spondylitis-clinical and MRI results of a 52-week open-label trial. Arthritis and Rheumatism; 2006; 54: 678-681.
106. van der Heijde D., Kivitz A., et al. Adalimumab therapy results in significant reductions of signs and symptoms in subjects with ankylosing spondylitis: the ATLAS trial. Arthritis and Rheumatism 52 supplement 1 (2005) S281
107. Braun J., Davis J., Dougados M., et al. First update of the International ASAS Consensus Statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases 65 3 (2006) 316-320
108. Van den Bosch F., Kruithof E., De Vos M., et al. Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet 356 (2000) 1821-1822
109. Generini S., Giacomelli R., Fedi R., et al. Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. Annals of the Rheumatic Diseases 63 (2004) 1664-1669
110. Marzo-Ortega H., McGonagle D., O'Connor P., and Emery P. Efficacy of etanercept for treatment of Crohn's related spondyloarthritis but not colitis. Annals of the Rheumatic Diseases 62 (2003) 74-76
111. Herfarth H., Obermeier F., Andus T., et al. Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn's disease. The American Journal of Gastroenterology 97 (2002) 2688-2690
112. Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. ACCENT I study group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359 (2002) 1541-1549
113. Rutgeerts P., Sandborn W.J., Feagan B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. The New England Journal of Medicine 353 (2005) 2462-2476
114. Jarnerot G., Hertervig E., Friis-Liby I., et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 128 (2005) 1805-1811
115. D'Haens G., Swijsen C., Noman M., et al. Etanercept in the treatment of active refractory Crohn's disease: a single-center pilot trial. The American Journal of Gastroenterology 96 (2001) 2564-2568
116. Sandborn W.J., Hanauer S.B., Katz S., et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121 (2001) 1088-1094
117. Baraliakos X., Brandt J., Listing J., et al. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data. Arthritis and Rheumatism 53 (2005) 856-863
118. Davis Jr. J.C., Van Der Heijde D., Braun J., et al. Enbrel Ankylosing Spondylitis Study Group. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis and Rheumatism 48 (2003) 3230-3236
119. Oh J., Arkfeld D.G., and Horwitz D.A. Development of Crohn's disease in a patient taking etanercept. The Journal of Rheumatology 32 (2005) 752-753
120. Rudwaleit M., Baraliakos X., Listing J., et al. Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept. Annals of the Rheumatic Diseases 64 (2005) 1305-1310
121. Van den Brande J.M., Braat H., van den Brink G.R., et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 124 (2003) 1774-1785
122. Di Sabatino A., Ciccocioppo R., Cinque B., et al. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease. Gut 53 (2004) 70-77
123. Sandborn W.J., Hanauer S., Loftus Jr. E.V., et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. The American Journal of Gastroenterology 99 (2004) 1984-1989
124. Papadakis K.A., Shaye O.A., Vasiliauskas E.A., et al. Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. The American Journal of Gastroenterology 100 (2005) 75-79